Jinyu Bio-Technology Co. - Public Comps and Valuation Multiples

Jinyu Bio-Technology Co. Overview

About Jinyu Bio-Technology Co.

Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.

Founded

1992

HQ

Employees

907

Website

jinyu.com.cn

Sectors

Biopharmaceuticals
Vaccines & Immunotherapies
BioTech

Financials

Last FY Revenue $180M

Last FY EBITDA $49.8M

EV

$2.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Jinyu Bio-Technology Co. Financials

See Jinyu Bio-Technology Co. valuation multiples based on analyst estimates

Jinyu Bio-Technology Co. P&L

In the most recent fiscal year, Jinyu Bio-Technology Co. reported revenue of $180M and EBITDA of $49.8M.

Jinyu Bio-Technology Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Jinyu Bio-Technology Co. valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$180M	XXX	XXX	XXX
Gross Profit	XXX	$96.9M	XXX	XXX	XXX
Gross Margin	XXX	54%	XXX	XXX	XXX
EBITDA	XXX	$49.8M	XXX	XXX	XXX
EBITDA Margin	XXX	28%	XXX	XXX	XXX
EBIT	XXX	$20.6M	XXX	XXX	XXX
EBIT Margin	XXX	11%	XXX	XXX	XXX
Net Profit	XXX	$15.6M	XXX	XXX	XXX
Net Margin	XXX	9%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Jinyu Bio-Technology Co. including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Jinyu Bio-Technology Co. achieved $180M in revenue and $49.8M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$180M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$96.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	53.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$49.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	27.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$20.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	11.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$15.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	8.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Jinyu Bio-Technology Co.

This financial data table provides comprehensive performance metrics for Jinyu Bio-Technology Co., a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Jinyu Bio-Technology Co. reported $180M in total revenue.
Fiscal year EBITDA was $49.8M.
The company maintained a gross profit margin of 53.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 27.7%.
Net profit margin reached 8.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Jinyu Bio-Technology Co.. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Jinyu Bio-Technology Co. Stock Performance

Jinyu Bio-Technology Co. has current market cap of CNY 20.1B (or $2.9B), and EV of CNY 18.7B (or $2.7B).

Market Cap Evolution

Jinyu Bio-Technology Co. Stock Data

As of January 30, 2026, Jinyu Bio-Technology Co.'s stock price is CNY 18 (or $3).

See Jinyu Bio-Technology Co. trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.7B	$2.9B	XXX	XXX	XXX	XXX	$0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Jinyu Bio-Technology Co. Valuation Multiples

Jinyu Bio-Technology Co.'s trades at 14.9x EV/Revenue multiple, and 53.8x EV/EBITDA.

See valuation multiples for Jinyu Bio-Technology Co. and 15K+ public comps

Jinyu Bio-Technology Co. Financial Valuation Multiples

As of January 30, 2026, Jinyu Bio-Technology Co. has market cap of $2.9B and EV of $2.7B.

Equity research analysts estimate Jinyu Bio-Technology Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Jinyu Bio-Technology Co.'s P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$2.9B	XXX	$2.9B	XXX	XXX	XXX
EV (current)	$2.7B	XXX	$2.7B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	14.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	53.8x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	130.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	184.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	93.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Jinyu Bio-Technology Co. Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Jinyu Bio-Technology Co. Margins & Growth Rates

Jinyu Bio-Technology Co.'s revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Jinyu Bio-Technology Co.'s rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Jinyu Bio-Technology Co.'s rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Jinyu Bio-Technology Co. and other 15K+ public comps

Jinyu Bio-Technology Co. Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	18%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	11%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	42%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial